Aptus Biosciences

Executive Summary

Aptus Biosciences is a private biotechnology company founded in 2018 and headquartered in San Diego, California, with a laboratory in Alachua, Florida. The company specializes in chemically modified DNA aptamer technology to develop high-affinity reagents for diagnostic applications in neurology, oncology, cardiology, and infectious diseases. Its core platform aims to improve early disease detection and prognosis by creating novel affinity reagents that offer advantages over traditional antibodies in terms of stability, scalability, and reproducibility. Aptus is currently in the pre-revenue stage with no disclosed funding rounds, but its technology has potential to address significant unmet needs in liquid biopsy and point-of-care diagnostics. The company's progress is relatively early-stage, with limited public information on clinical validation or commercial partnerships, which tempers near-term expectations.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership or licensing deal for diagnostic panel development40% success
• Q1 2027Initial clinical study results for aptamer-based neurology or oncology assay30% success
• Q2 2026Series A funding round to support platform commercialization50% success